A 69-metre long rounded LED structure featuring content that responds dynamically to passenger flow has been installed at ...

Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients ...

First registrational study to specifically evaluate a targeted treatment for patients living with ocular MGResults support planned Supplemental Biologics License Application (sBLA) submission to ...

Efgartigimod led to statistically significant improvement in key symptoms of ocular myasthenia gravis compared with placebo in a phase 3 trial.

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced ...

Three manatees are ready to make their debut in a new Jacksonville Zoo and Botanical Gardens exhibit. Here's a preview.

X recently announced results from additional analyses of its blockbuster FcRn inhibitor Vyvgart in the phase III Adapt Oculus study. The study evaluated the efficacy and safety of Vyvgart administered ...

Efgartigimod alfa–hyaluronidase significantly improves ocular symptoms in adults with ocular myasthenia gravis, according to phase 3 trial data.

Netherlands-based immunology company argenx has announced positive topline results from the Phase III ADAPT OCULUS study of Vyvgart (efgartigimod alfa and hyaluronidase-qvfc) in adults with ocular ...

First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics ...

Nanolumens and Ford AV collaborate to integrate 220-foot continuous custom Nixel Series display.

As the most important annual XR event on our calendar, we’re excited to once again be able to offer an exclusive 20% discount ...